NCT05473117

Brief Summary

Ischaemic Heart Disease (IHD) is the worlds leading cause of death. IHD is often caused by a narrowing of the coronary arteries, which prevents blood from flowing to the heart muscle, causing pain and damage to the heart. If an individual has a myocardial infarction (MI), parts of the heart that are damaged cannot be repaired. Therefore, it is important to identify and treat the narrowing of the arteries before an MI occurs. At present there are 2 main methods of identifying narrowing of the arteries. The first is an invasive procedure, the other using a CT scan. Whilst both methods are effective, they entail risk. The invasive procedure can damage the coronary arteries, whilst the CT scan exposes patients to radiation and contrast, which can increase the risk of cancer and allergic reactions. Magnetic Resonance (MR) scanning is an alternative to these methods, but it has been limited in use in the past due, in part, to the high technical knowledge required to obtain images. In addition, there is a degree of subjectivity in the selection of the mid-diastolic rest period, potentially affecting consistency of results. This means it is difficult to use in a day-to-day hospital environment. However, recent technological developments using artificial intelligence mean that images can be acquired in a more automated and consistent fashion. This new scan has yet to be tested in a clinical trial. Therefore, the objective of the clinical study is to test this new scan to determine its efficacy. 230 patients at 5 sites at risk of coronary artery disease, who have been referred for invasive coronary angiography, will undergo both their angiography and the new MR scan. The MR scan will then be compared to CCTA for diagnostic accuracy and image quality. The investigators hypothesise that the new MR scan will have the same diagnostic accuracy as invasive coronary angiography, with no differences in interpretation of the images across the 5 different hospitals. If proven effective, this would demonstrate that MR scanning of the coronary arteries could prove a safe, clinically useful alternative to both CT scanning and invasive assessment of coronary artery narrowing. In addition, if there is no difference across different locations, it would demonstrate that these scans can be performed consistently, facilitating implementation on a healthcare-system wide basis.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
5mo left

Started Jun 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Jun 2024Dec 2026

First Submitted

Initial submission to the registry

July 19, 2022

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 25, 2022

Completed
1.9 years until next milestone

Study Start

First participant enrolled

June 1, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

June 22, 2023

Status Verified

June 1, 2023

Enrollment Period

1.5 years

First QC Date

July 19, 2022

Last Update Submit

June 19, 2023

Conditions

Keywords

Coronary Magnetic Resonance AngiographyCoronary Artery StenosisArtificial Intelligence

Outcome Measures

Primary Outcomes (1)

  • Haemodynamically significant CAD

    Number of patients with haemodynamically significant CAD, defined as coronary artery diameter stenosis ≥50%, as assessed by CMRA, compared to CCTA.

    CCTA will take place on clinical indication to investigate risk of CAD following an episode of chest pain. CMRA will be acquired ± 4 weeks compared to CCTA.

Secondary Outcomes (1)

  • Image quality

    CCTA will take place on clinical indication to investigate risk of CAD following an episode of chest pain. CMRA will be acquired ± 4 weeks compared to CCTA.

Other Outcomes (2)

  • Inter-reader variability in interpretation of the CMRA protocol

    CCTA will take place on clinical indication to investigate risk of CAD following an episode of chest pain. CMRA will be acquired ± 4 weeks compared to CCTA.

  • Pulse rate

    CCTA will take place on clinical indication to investigate risk of CAD following an episode of chest pain. CMRA will be acquired ± 4 weeks compared to CCTA.

Study Arms (1)

Patient Group

A single cohort consisting of 230 patients referred for CT Coronary Angiography (CCTA) at risk of coronary artery disease. All patients will undergo both CCTA and CMRA

Diagnostic Test: Coronary Magnetic Resonance Angiography (CMRA)

Interventions

A highly optimised CMRA protocol integrating advanced, automated software for detection of coronary artery stenosis

Patient Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will be drawn from individuals referred to CCTA for assessment of the coronary arteries living in the regions of the 5 study sites, which are based at the following hospitals: * Aarhus University Hospital (Aarhus, Denmark) * Herlev-Gentofte Hospital (Copenhagen, Denmark) * Kings College London (London, UK) * Hammersmith Hospital (London, UK) * Rigshospitalet (Copenhagen, Denmark)

You may qualify if:

  • ≥18 years old
  • Subject has provided informed written consent
  • BMI \< 35
  • Sinus Rhythm
  • Undergoing CCTA within 28 days

You may not qualify if:

  • Any contraindication to CMR
  • Previous coronary revascularisation
  • Inability to take sublingual nitroglycerin
  • Irregular heart rate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aarhus University Hospital

Aarhus, 8200, Denmark

Location

Related Publications (1)

  • Wood G, Hajhosseiny R, Pedersen AU, Littlewood S, Hansen TJ, Neji R, Kunze KP, Wetzl J, Norgaard BL, Jensen JM, Maeng M, Madsen PL, Vejlstrup N, Prieto C, Botnar RM, Kim WY. Image navigator-based, automated coronary magnetic resonance angiography for the detection of coronary artery stenosis. J Cardiovasc Magn Reson. 2024 Winter;26(2):101097. doi: 10.1016/j.jocmr.2024.101097. Epub 2024 Sep 16.

MeSH Terms

Conditions

Coronary Stenosis

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Won Yong Kim

    Department of Cardiology, Aarhus University Hospital

    STUDY CHAIR

Central Study Contacts

Alexandra Pedersen

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

July 19, 2022

First Posted

July 25, 2022

Study Start

June 1, 2024

Primary Completion

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

June 22, 2023

Record last verified: 2023-06

Locations